Should Pregnant Women Skip Gestational Diabetes Screening?

Should pregnant individuals skip gestational diabetes screening? The short answer is no—routine screening is strongly recommended for all pregnant individuals, regardless of perceived risk factors.

Gestational diabetes mellitus (GDM) is a form of glucose intolerance first diagnosed during pregnancy. It affects approximately 2–10% of pregnancies globally and carries significant implications for both maternal and fetal health. Undiagnosed or poorly managed GDM increases the risk of macrosomia (excessive fetal growth), shoulder dystocia, neonatal hypoglycemia, preterm birth, preeclampsia, and cesarean delivery. Long-term, it also elevates the mother’s future risk of type 2 diabetes and cardiovascular disease.

Current guidelines—including those from the American College of Obstetricians and Gynecologists (ACOG), the International Association of Diabetes and Pregnancy Study Groups (IADPSG), and the U.S. Preventive Services Task Force (USPSTF)—recommend universal screening between 24 and 28 weeks’ gestation. The standard approach involves a two-step process in many U.S. practices: a 50-gram oral glucose challenge test (OGCT), followed by a diagnostic 100-gram oral glucose tolerance test (OGTT) if the OGCT result exceeds threshold (typically ≥130 or ≥140 mg/dL, depending on the cutoff used). Alternatively, some centers use a one-step 75-gram OGTT with IADPSG criteria, diagnosing GDM if any single value meets or exceeds fasting ≥92 mg/dL, 1-hour ≥180 mg/dL, or 2-hour ≥153 mg/dL.

While certain risk factors—such as obesity, advanced maternal age, family history of diabetes, prior GDM, or ethnicity associated with higher prevalence (e.g., South Asian, Hispanic, Black, or Indigenous ancestry)—increase susceptibility, up to half of all GDM cases occur in individuals without traditional risk markers. Relying solely on clinical judgment or selective screening misses these cases and compromises care equity and safety.

Early identification enables timely intervention: medical nutrition therapy, physical activity counseling, self-monitoring of blood glucose, and, when necessary, pharmacologic treatment (e.g., insulin or metformin). These interventions have been shown to reduce adverse outcomes without increasing cesarean rates or neonatal complications.

In summary, skipping gestational diabetes screening is not evidence-based practice. Universal screening remains a cornerstone of prenatal care—not because every pregnancy will develop GDM, but because early detection and management significantly improve outcomes for both parent and baby.